source
- FDA pushes back PDUFA date for Capricor's Duchenne therapy to review new dataThe U.S. Food and Drug Administration announced it has extended the PDUFA target date for Capricor Therapeutics' investigational Duchenne muscular dystrophy treatment. The agency said the extensio…
- Medicaid coverage for GLP-1 weight-loss drugs stalls, only Indiana signs onPresident Trump pledged to broaden Medicaid access to costly GLP-1 obesity medications by letting states negotiate prices directly with manufacturers. The rollout depended on state participation,…